Suzano (SUZB3) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
7 Nov, 2025Executive summary
Achieved a 7% year-over-year reduction in cash cost, now below BRL 800 per ton, driven by operational efficiencies, lower wood and input costs, and FX appreciation.
Adjusted EBITDA reached R$5.2 billion, down 20% year-over-year, mainly due to lower pulp prices and currency depreciation, partially offset by higher sales volumes and improved efficiency.
Net income was R$1,961 million, a 39% decrease year-over-year, reflecting lower financial results and reduced net revenue.
US packaging business and paperboard assets delivered their first positive EBITDA since acquisition.
Focus remains on extracting value from recent investments, including Suzano Packaging, the new tissue mill in Aracruz, and the JV with Cascades.
Financial highlights
Leverage in dollar terms increased to 3.3x due to lower LTM EBITDA from reduced pulp prices, while net debt remained stable quarter-on-quarter.
Adjusted EBITDA margin was 43%, down from 53% a year ago; free cash flow yield (LTM) was 18.1%, up 1.2 p.p. year-over-year.
Liquidity stood at US$6.5 billion, up from US$5.7 billion a year ago.
Issued $1 billion in new 10-year bonds at the lowest corporate spread in company history and repurchased short-term bonds, extending average debt maturity to 80 months at a stable 5% cost.
Net revenue totaled R$12,153 million, a 1% decrease year-over-year, with 81% from exports.
Outlook and guidance
Confident in delivering the most competitive quarterly cash cost in Q4 2024-2025 and maintaining a full-year average near Q4 2024 levels.
CAPEX guidance for 2025 reaffirmed at BRL 13.3 billion, with a declining trend expected for 2026 as major projects conclude.
Further reduction in cash production cost expected for 4Q25, with continued focus on operational efficiency and cost control.
New tissue mill in Aracruz and JV with K-C/Cascades progressing as planned, with benefits expected from 4Q25.
Latest events from Suzano
- Record sales, cost discipline, and strong liquidity support a positive outlook.SUZB3
Q4 202511 Feb 2026 - EBITDA up 60% year-over-year, but net loss of R$3.77B on FX and derivative impacts.SUZB3
Q2 20241 Feb 2026 - EBITDA and sales volumes surged, with Ribas ramp-up and acquisitions boosting performance.SUZB3
Q3 202418 Jan 2026 - Cost leadership, operational excellence, and disciplined capital allocation drive growth.SUZB3
Investor Day 202411 Jan 2026 - Record sales and EBITDA driven by Ribas ramp-up, but FX losses led to a net loss.SUZB3
Q4 20248 Jan 2026 - Focus is on competitiveness, cost reduction, and disciplined growth amid market shifts.SUZB3
Investor Day 202512 Dec 2025 - Strong sales growth, robust cash flow, and major strategic moves marked the quarter.SUZB3
Q2 202523 Nov 2025 - Net income rose to R$6.3B in 1Q25, with stable leverage and strong free cash flow.SUZB3
Q1 202518 Nov 2025 - JV creates a global tissue leader with $3.3bn revenue, $175M synergies, and strong diversification.SUZB3
Investor Update12 Nov 2025